IL-6 as a therapeutic target to suppress cancer cell invasiveness and metastases is supported by data from numerous cancers including pancreatic, head and neck, breast, ovarian, non-small-cell lung cancer, and melanoma [Raškova et al., 2022]. The gene discussed is IL6; the disease is melanoma.